Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Founding Intercept CEO Pruzanski prepares to hand over the reins 

December 11, 2020 2:16 AM UTC

For the first time in its nearly 20-year history, Intercept will ring in the New Year with a new face in the corner office.

After guiding Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) through its launch in the years immediately after the bursting of the genomics bubble to an $86 million IPO in 2012 and the approval of its first marketed product in Ocaliva obeticholic acid, President and CEO Mark Pruzanski is handing over the reins to his COO, Jerry Durso. Pruzanski will become an adviser to the company and remain on its board...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Intercept Pharmaceuticals Inc.